Scinosen was born in response to the national implementation of the MAH (Marketing Authorization Holder) system, and is the only professional company in China's gene drug field that has achieved full coverage from research and development, industrialization to clinical application. The Sinovac Genomics team of scientists and core industrialization team - is the creator of the world's first gene drug (now known as Yasheng), and has established a complete set of technical standards for the large-scale production process and quality control of recombinant adenovirus biologics. This standard has established China's leading position in the world in the large-scale industrialization of adenovirus gene therapy drugs. We have established drug production quality management standards that comply with China's NMPA, the US FDA, and the EU EMA. Based on the team's over 20 years of experience in this industry, the company focuses on providing professional virus vector based gene drug CDMO services to the world.